Ophthalmology Times Europe - Dry Eye http://www.oteurope.com/ophthalmologytimeseurope/Dry+Eye/Article/list/46478 ophthalmology news, features, events and interviews in cataract, refractive, glaucoma, retina and much more. 2013-06-19T05:09:09Z New financing round for dry eye portfolio http://www.oteurope.com/ophthalmologytimeseurope/Dry+Eye/New-financing-round-for-dry-eye-portfolio/ArticleStandard/Article/detail/811563?contextCategoryId=46478&ref=25 Novaliq has secured €13.9 million in a fifth round of financing for a dry eye portfolio. 2013-04-24T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/172013/811563null HTML High index of suspicion required for SS http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/High-index-of-suspicion-required-for-SS/ArticleStandard/Article/detail/790241?contextCategoryId=46478&ref=25 A high index of suspicion is required for underlying Sjögren's syndrome (SS) in patients with clinically significant aqueous-deficient dry eye. 2012-10-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/392012/790241null HTML The ideal drop through the eyes of doctors and patients http://www.oteurope.com/ophthalmologytimeseurope/Other/The-ideal-drop-through-the-eyes-of-doctors-and-pat/ArticleStandard/Article/detail/690290?contextCategoryId=46478&ref=25 Five steps and the criteria for success, as seen through the eyes of patients and their doctors... 2010-09-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/412010/690290null XML Contact induced dry eye http://www.oteurope.com/ophthalmologytimeseurope/Other/Contact-induced-dry-eye/ArticleStandard/Article/detail/690284?contextCategoryId=46478&ref=25 Understanding the problems of contact lens induced dry eye 2010-09-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/412010/690284null XML Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Tear-cytokine-and-chemokine-analysis-and-clinical-/ArticleStandard/Article/detail/674504?contextCategoryId=46478&ref=25 In a sample of moderate evaporative-type dry eye disease patients Enriquez-de-Salamanca et al., elevated five inflammatory molecules. Fracktalkine was demonstrated to be present and elevated in tears in human DED. 2010-06-17T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/252010/674504null HTML Out with the old and in with the new http://www.oteurope.com/ophthalmologytimeseurope/Dry+Eye/Out-with-the-old-and-in-with-the-new/ArticleStandard/Article/detail/626898?contextCategoryId=46478&ref=25 A comparison of an older nanoliter osometer and a newer osometer shows that both devices are effective in measuring tear osmolarity and produce comparable measurements. 2009-09-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/382009/626898null XML Intraductal meibomian gland probing reduces inflammation http://www.oteurope.com/ophthalmologytimeseurope/Dry+Eye/Intraductal-meibomian-gland-probing-reduces-inflam/ArticleStandard/Article/detail/626892?contextCategoryId=46478&ref=25 A new technique of intraductal meibomian gland probing using disposable cannulas of various lengths appears highly effective in providing quick and lasting relief from inflammatory sysmptoms of obstructive meibomian gland disease. 2009-09-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/382009/626892null XML Insert improves symptoms and quality of life for patients with dry eye http://www.oteurope.com/ophthalmologytimeseurope/Dry+Eye/Insert-improves-symptoms-and-quality-of-life-for-p/ArticleStandard/Article/detail/626900?contextCategoryId=46478&ref=25 The use of hydroxypropyl cellulose can significantly improve the symptoms of dry eye, resulting in increased quality of life. 2009-09-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/382009/626900null XML New options in treating lid wiper epitheliopathy http://www.oteurope.com/ophthalmologytimeseurope/Dry+Eye/New-options-in-treating-lid-wiper-epitheliopathy/ArticleStandard/Article/detail/626903?contextCategoryId=46478&ref=25 An oil-in-water and a corticosteroid were both effective in eliminating the signs and symptoms of lid wiper epitheliopathy after a 1-month active treatment phase in a recent study. Improvement was effectively maintained with the emollient eye drops in all patients over a 12-month period. 2009-09-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/382009/626903null XML Cyclosporine helps prevent progression of dry eye http://www.oteurope.com/ophthalmologytimeseurope/Dry+Eye/Cyclosporine-helps-prevent-progression-of-dry-eye/ArticleStandard/Article/detail/626896?contextCategoryId=46478&ref=25 A recent study showed that moderate to sever dry eye disease can be best treated with anti-inflammatory medications such as topical cyclosporine. According to one ophthalmologist, cyclosporine can significantly limit progression of dry eye disease and should be considered a 'go-to' therapy for this patient population. 2009-09-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/382009/626896null XML Severe trachomatous dry eye treatment http://www.oteurope.com/ophthalmologytimeseurope/Dry+Eye/Severe-trachomatous-dry-eye-treatment/ArticleStandard/Article/detail/615861?contextCategoryId=46478&ref=25 Dr Mustafa Guzey and colleagues have found topical cyclosporine A to be effective in treating severe trachomatous dry eye in a recent study published in Clinical & Experimental Ophthalmology. 2009-08-05T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/322009/615861null HTML Regimen change cuts eye drops use in half http://www.oteurope.com/ophthalmologytimeseurope/Dry+Eye/Regimen-change-cuts-eye-drops-use-in-half/ArticleStandard/Article/detail/605267?contextCategoryId=46478&ref=25 Nerve damage associated ocular dryness improved dramatically with hyaluronic acid-based lubricating eye drops explains Claes Feinbaum M.Sc. Professor Emeritus Optometry, Vision4You, Lund, Sweden. 2009-06-24T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/262009/605267null HTML High viscosity eye drop improves T-BUT in VDT users http://www.oteurope.com/ophthalmologytimeseurope/Dry+Eye/High-viscosity-eye-drop-improves-T-BUT-in-VDT-user/ArticleStandard/Article/detail/605270?contextCategoryId=46478&ref=25 High molecular weight increases blink rate and helps eye drops retain moisture on the ocular surface according to Professor Giancarlo Montani an optometrist FIACLE and a professor of optometry at the Universita del Salento in Italy. 2009-06-24T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/262009/605270null HTML Non invasive ocular drug delivery trial promising for dry eye http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Non-invasive-ocular-drug-delivery-trial-promising-/ArticleStandard/Article/detail/602108?contextCategoryId=46478&ref=25 In a dry eye Phase II clinical trial EyeGate Pharma reports that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES). 2009-06-10T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/242009/602108null HTML TearLab Osmolarity System cleared by FDA http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/TearLab-Osmolarity-System-cleared-by-FDA/ArticleStandard/Article/detail/598746?contextCategoryId=46478&ref=25 The TearLab Osmolarity System is intended to measure the osmolarity of human tears to aid in the diagnosis of patients with signs or symptoms of Dry Eye Disease (DED) in conjunction with other methods of clinical evaluation. It is now in a position to be marketed to clinincal facilities in the United States, having received its FDA 510(k) clearance. 2009-05-21T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/212009/598746null HTML False hope for dry eye? http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/False-hope-for-dry-eye/ArticleStandard/Article/detail/596103?contextCategoryId=46478&ref=25 An OTEurope story we ran a couple of weeks ago clearly resonated with reader, Peter Raus in Belgium. Read on to see what he thought. 2009-05-06T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/182009/596103null HTML Not a dry eye in the house http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Not-a-dry-eye-in-the-house/ArticleStandard/Article/detail/594145?contextCategoryId=46478&ref=25 Significant improvement in signs and symptoms in patients suffering from moderate-to-severe dry eye syndrome have been found following the Phase II trial of Cyclokat, the formulation of cyclosporine by French pharmaceutical ophthalmic company Novagali Pharma. 2009-04-22T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/172009/594145null HTML Testing dry eye diagnostic system http://www.oteurope.com/ophthalmologytimeseurope/Dry+Eye/Testing-dry-eye-diagnostic-system/ArticleStandard/Article/detail/587346?contextCategoryId=46478&ref=25 The TearLab Osmolarity Core Validation Study, a multicentre international clinical study assessing the efficacy of the TearLab Osmolarity System for the diagnosis of dry eye disease, has been launched by the system's maker, OccuLogix Inc, and sponsored by Alcon. 2009-03-18T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/122009/587346null HTML Co-promoting retinal health and meibomitis therapies http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Co-promoting-retinal-health-and-meibomitis-therapi/ArticleStandard/Article/detail/582698?contextCategoryId=46478&ref=25 Sirion Therapeutics Inc and Advanced Vision Research Inc (AVR) have agreed to co-promote AVR's MacuTrition (a nutritional supplement promoting retinal health) and NutiDox Convenience Kit (a meibomian gland therapy) in the US. 2009-02-25T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082009/582698null HTML Dry eye solution moves into Phase III http://www.oteurope.com/ophthalmologytimeseurope/Refractive+news/Dry-eye-solution-moves-into-Phase-III/ArticleStandard/Article/detail/580359?contextCategoryId=46478&ref=25 Prolacria (diquafosol tetrasodium ophthalmic solution) 2% has entered a Phase III trial for the treatment of dry eye disease, according to an announcement from the solution's developer, Inspire Pharmaceuticals, Inc. 2009-02-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/072009/580359null HTML Dry eye treatment nearing approval http://www.oteurope.com/ophthalmologytimeseurope/Dry+Eye/Dry-eye-treatment-nearing-approval/ArticleStandard/Article/detail/577228?contextCategoryId=46478&ref=25 ISTA Pharmaceuticals' dry eye candidate, ecabet sodium, has successfully completed Phase IIb testing and will soon be progressing to Phase III trials taking it a step closer to regulatory approval. 2009-01-28T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042009/577228null HTML Once-daily insert designed to provide lasting dry eye relief http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Once-daily-insert-designed-to-provide-lasting-dry-/ArticleStandard/Article/detail/531161?contextCategoryId=46478&ref=25 A hydroxypropyl cellulose ophthalmic insert (Lacrisert, Aton Pharma) is a preservative-free product recommended for once-daily insertion in the inferior cul-de-sac. Its convenience, efficacy, and safety make it a valuable option for the management of dry eye disease. 2008-07-28T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/302008/531161null XML